Xanthine oxidase-IN-21
Xanthine oxidase-IN-21, a Genipin (HY-17389) derivative, is an orally active mixed competitive xanthine oxidase (XOD) inhibitor with an IC50 of 0.68 μM. Xanthine oxidase-IN-21 reduces renal fibrosis by decreasing α-SMA expression and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α through NF-κB pathway regulation. Xanthine oxidase-IN-21 also inhibits URAT1 and GLUT9 expression, promoting uric acid excretion and lowering serum uric acid levels. Xanthine oxidase-IN-21 shows significantly hepatorenal protection activity. Xanthine oxidase-IN-21 can be used for the research of hyperuricemia.
For research use only. We do not sell to patients.
- Formula: C20H22N2O3
- Molecular Weight:338.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Xanthine oxidase 0.68 μM (IC50) |
NF-κB |
IL-1β |
IL-6 |
Xanthine oxidase-IN-21 (compound 5b) (0.1, 1, 10, 100, and 200 μM; 24 h) is non-cytotoxicity to HK-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A hyperuricemia model was established in KM (male, 20 g) by injection of Adenine (HY-B0152) and Potassium oxonate (PO) (HY-17511)[1]
-
Dosage:10 mg/kg, 20 mg/kg, 30 mg/kg
-
Administration:Oral; daily; for 2 weeks
-
Result:Significantly reduced serum uric acid (UA) levels, creatinine (Cr), and blood urea nitrogen (BUN) in hyperuricemic mice.
Also decreased the levels of AST and ALT, indicating protection of liver and kidney function.
Ameliorated kidney and liver damage, reduced inflammatory cytokine levels (IL-1β, IL-6, TNF-α), and decreased the expression of pro-inflammatory markers (p-ERK, p-p38, p65 NF-κB).
Reduced the expression of uric acid transporters (URAT1, GLUT9) and inhibited XOD activity, which is a key target in hyperuricemia.
Chemical Information
-
Molecular Weight 338.40
-
Formula C20H22N2O3
-
SMILES
O=C(OC)C1=CCC(OC)C2C1CC=C2CNC3=CC=C(C#N)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Xanthine oxidase-IN-21 Related Classifications
HY-180271 Related Classifications
Powered by Bioz